PYRROLOBENZODIAZEPINKONJUGATE

European patent · EP3612537 · In force

Register entry

Publication number
EP3612537
Application number
EP18718452
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 18, 2018
Published
Feb 26, 2020
Granted
Jul 13, 2022
Protection ends at the latest
Apr 17, 2038
Next annual fee due
Apr 30, 2027
IPC classes
C07D 519/00 (2006.01)
A61P 35/00 (2006.01)
A61K 47/68 (2017.01)
C07K 5/062 (2006.01)
Priority
GB 201706133 18.04.2017
GB 201721337 19.12.2017
PCT application
PCT/EP2018/059846 18.04.2018
PCT publication
WO2018/192944 25.10.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  4. May 24, 2023

    Change

    Published in Swissreg on 24.05.2023

  5. May 1, 2023

    Change

    Published in Swissreg on 01.05.2023

  6. Jul 28, 2022

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 28.07.2022

  7. Jul 13, 2022

    Granted

    Published in Swissreg on 13.07.2022

Parties

Holder

Medimmune Limited

Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH, GB

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

GREGSON, Stephen John

Cambridge Cambridgeshire CB21 6GH, GB

HOWARD, Philip Wilson

Cambridge Cambridgeshire CB21 6GH, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.